The first domestically produced ADC drug has been fully approved for marketing in China. Kelunbote takes the lead. | Quick announcement

① Sichuan Kelun Pharmaceutical's holding subsidiary Kelun Botai has received domestic approval for the marketing of Lukanasatuzumab. ② This drug is used for the treatment of unresectable locally advanced or metastatic breast cancer and is the first domestically produced ADC to receive full approval for marketing in the country. ③ Two additional new drug applications for Lukanasatuzumab have been accepted by the NMPA.

cls.cnNov 27 21:14

Subsidiary's slow research and development progress questioned, zhejiang huahai pharmaceutical responded: "More than 10 products have entered the clinical research stage" | Direct hit on earnings conference

①At the earnings conference, zhejiang huahai pharmaceutical's research and development pipeline progress was questioned by investors, to which the company's secretary to the board, Zhu Yonghua, introduced the situation of the ongoing pipeline. ②On the zhejiang huahai pharmaceutical side, influenced by factors such as growth in original research big clients, revenue from active pharmaceutical ingredient and formulation business has increased in the first three quarters of this year.

cls.cnNov 20 18:45

Repurchase amount does not meet the standard, jilin yatai group is ordered by regulators to make corrections | Quick read announcement

1. When the repurchase term expires, jilin yatai repurchases amount falls below the lower limit of the repurchase total, and the Jilin Securities Regulatory Bureau requires correction. 2. Jilin Securities Regulatory Bureau decides to take corrective regulatory measures against the company and record it in the securities and futures market integrity file.

cls.cnNov 8 23:46

Investors are paying attention to the progress of FT606. shandong lukang pharmaceutical did not directly respond to the production time | Live coverage of the earnings conference.

①The progress of the company's new synthetic biotechnology material product FT606 has attracted much attention. ②The pharmaceutical industry was in the traditional off-season in the third quarter, leading to a decline in the company's Q3 earnings. ③During the earnings conference, a questioner who claimed to be an investor expressed dissatisfaction with the lack of interaction.

cls.cnNov 8 21:51

80-year-old 'cotton giant' Lu Keping was sentenced and fined 0.23 billion yuan. The last listed company of the 'Sunshine Series' is in jeopardy. | Speed ​​reading announcement

①Jiangsu Sihuan Bioengineering announced that its controlling shareholder Lu Keping was sentenced to 3 years in prison and 4 years of probation for insider trading, with illegal gains of 0.232 billion yuan confiscated; ②Shares of jinyu bio-technology held by Lu Keping's concerted parties will be auctioned judicially, which may result in Lu Keping losing control of the company; ③Three out of the four "Yangguang Series" listed companies have been delisted, and jinyu bio-technology also faces delisting risks.

cls.cnNov 5 23:54

The annual disclosure assessment results are out! 471 companies have reached the "double A+ hundred billion" threshold, while 577 companies have been downgraded by the exchange.

①In the fiscal year 2023-2024, 577 listed companies were downgraded by the exchange, with hainan poly pharm's disclosure rating plummeting from A to D; ②As of now, there are a total of 31 listed companies in A-shares whose disclosure rating has been D for three consecutive years, with 21 companies being labeled as "patriotic."; ③Currently, there are 471 A-share listed companies that have reached the threshold of "two consecutive years of A+ with a market cap of over one hundred billion", including 174 privately-owned enterprises.

cls.cnOct 14 15:16